deltatrials
Terminated PHASE1 INTERVENTIONAL 3-arm NCT03449030

A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-164, an Antibody-Drug Conjugate, in Patients With Advanced Gastrointestinal Cancers Expressing Guanylyl Cyclase C

Sponsor: Millennium Pharmaceuticals, Inc.

Conditions Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies
Interventions 89Zr-TAK-164 TAK-164
Updated 13 times since 2018 Last updated: Feb 24, 2021 Started: Apr 23, 2018 Primary completion: Feb 27, 2020 Completion: Feb 27, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Insufficient clinical benefit to participants at the selected recommended phase 2 (RP2D) dose in Part A.

Other terminated trials from Millennium Pharmaceuticals, Inc.

More terminations from Millennium Pharmaceuticals, Inc.

Listed as NCT03449030, this PHASE1 trial focuses on Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies and remains terminated or withdrawn. Sponsored by Millennium Pharmaceuticals, Inc., it has been updated 13 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Dec 2018 · 6 months · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Sep 2019 · 8 months · monthly snapshot~Sep 2019 – ~Dec 2019 · 3 months · monthly snapshot~Dec 2019 – ~Mar 2020 · 3 months · monthly snapshot~Mar 2020 – ~May 2020 · 2 months · monthly snapshot~May 2020 – ~Jan 2021 · 8 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Dec 2021 · 8 months · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE1

  4. Apr 2021 — Dec 2021 [monthly]

    Terminated PHASE1

    Status: Completed → Terminated

  5. Jan 2021 — Apr 2021 [monthly]

    Completed PHASE1

▶ Show 8 earlier versions

  1. May 2020 — Jan 2021 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  2. Mar 2020 — May 2020 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  3. Dec 2019 — Mar 2020 [monthly]

    Recruiting PHASE1

  4. Sep 2019 — Dec 2019 [monthly]

    Recruiting PHASE1

  5. Jan 2019 — Sep 2019 [monthly]

    Recruiting PHASE1

  6. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE1

  7. Jun 2018 — Dec 2018 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  8. Mar 2018 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Millennium Pharmaceuticals, Inc.
Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations